Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (DE:1S1)
FRANKFURT:1S1
Viridian Therapeutics (1S1) Stock Price & Analysis
0 Followers
1S1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€10.20 - €25.20
Previous Close€14.3
Volume0.00
Average Volume (3M)273.00
Market Cap
€899.47M
Enterprise Value€730.60M
Total Cash (Recent Filing)$201.41M
Total Debt (Recent Filing)$20.00M
Price to Earnings (P/E)N/A
Beta0.12
Next Earnings
May 08, 2024EPS Estimate
-€1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding62,767,570
10 Day Avg. Volume0
30 Day Avg. Volume273
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.69
Price to Sales (P/S)499.45
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.93K
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.29
Forecast
1Y Price Target
€33.93Price Target Upside137.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Viridian Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial Strategy And Growth PotentialAnalyst maintains an Outperform rating on VRDN with a new target of $40, reflecting confidence in the company's financial strategy and growth potential.
Product Development MilestoneVRDN's nomination of VRDN-003 to be advanced as a subcutaneous product for Thyroid Eye Disease marks an important milestone.
Upcoming Data ReleaseAnticipated mid-2024, THRIVE pivotal data for Viridian Therapeutics' VRDN-001 could potentially bring positive developments.
Bears Say
Competitor ProgressWith competitor Amgen advancing their own subcutaneous Tepezza program, there is increased pressure on VRDN to execute effectively in a competitive market.
Financial ResultsLast quarter, Viridian reported earnings per share of -$1.35 versus the consensus of -$0.99 and the estimate of -$0.91, primarily due to severance costs for its outgoing CEO.
Market SentimentViridian's stock is faced with a high short interest, indicating that a significant portion of the market may be betting against the company's success.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
3.86% Other Institutional Investors
96.14% Public Companies and
Individual Investors
1S1 FAQ
What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest stock price was €10.20 and its highest was €25.20 in the past 12 months.
What is Viridian Therapeutics’s market cap?
Currently, no data Available
When is Viridian Therapeutics’s upcoming earnings report date?
Viridian Therapeutics’s upcoming earnings report date is May 08, 2024 which is yesterday.
How were Viridian Therapeutics’s earnings last quarter?
Viridian Therapeutics released its earnings results on Mar 13, 2024. The company reported -€1.254 earnings per share for the quarter, missing the consensus estimate of -€0.908 by -€0.346.
Is Viridian Therapeutics overvalued?
According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
Does Viridian Therapeutics pay dividends?
Viridian Therapeutics does not currently pay dividends.
What is Viridian Therapeutics’s EPS estimate?
Viridian Therapeutics’s EPS estimate is -€1.01.
How many shares outstanding does Viridian Therapeutics have?
Currently, no data Available
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Viridian Therapeutics reported an EPS of -€1.254 in its last earnings report, missing expectations of -€0.908. Following the earnings report the stock price went down -10.734%.
Which hedge fund is a major shareholder of Viridian Therapeutics?
Among the largest hedge funds holding Viridian Therapeutics’s share is Maverick Capital ltd. It holds Viridian Therapeutics’s shares valued at 51M.
---
Viridian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€33.93 (137.27% Upside)
€33.93 (137.27% Upside)
Blogger Sentiment
Bullish
DE:1S1 Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.43%
12-Months-Change
Fundamentals
Return on Equity
-56.80%
Trailing 12-Months
Asset Growth
12.72%
Trailing 12-Months
Company Description
Viridian Therapeutics
Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
---
1S1 Company Deck
---
1S1 Earnings Call
Q1 2023
0:00 / 0:00
---
1S1 Stock 12 Month Forecast
Average Price Target
€33.93
▲(137.27% Upside)
Technical Analysis
Viridian Therapeutics
―
Voyager Therapeutics
―
Avrobio
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering 1S1
1 Year
1 Year Success Rate
11/29 ratings generated profit
1 Year Average Return
-5.67%
reiterated a buy rating yesterday
Copying Laura Chico's trades and holding each position for 1 Year would result in 37.93% of your transactions generating a profit, with an average return of -5.67% per trade.
---